Regulation of hdm2 by stress-induced hdm2alt1 in tumor and nontumorigenic cell lines correlating with p53 stability

Cancer Research

Volumn 66, Issue 19, 2006, Pages 9467-9473

  Dias, Chrisanne S ^a   Liu, Yan ^a   Yau, Amy ^a   Westrick, Lindsay ^a   Evans, Susan C ^a  

^a OHIO UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; HDM2 ALT1 PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; CARCINOGENESIS; CELL DAMAGE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOPLASM; GAMMA RADIATION; HUMAN; HUMAN CELL; IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SPLICEOSOME; TUMOR CELL LINE; ULTRAVIOLET RADIATION;

ALTERNATIVE SPLICING; CARCINOMA; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CISPLATIN; DNA; DNA DAMAGE; EPITHELIAL CELLS; FEMALE; GAMMA RAYS; HOMEOSTASIS; HUMANS; NEOPLASM PROTEINS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; RNA, NEOPLASM; SUBCELLULAR FRACTIONS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 33750343019     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3013     Document Type: Article

References (24)

1. Cahilly-Snyder L, Yang-Feng T, Francke U, George DL. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 1987;13:235-44.
2. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991;10:1565-9.
3. Finlay CA. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993;13:301-6.
4. Brown DR, Thomas CA, Deb SP. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J 1998;17:2513-25.
5. Momand J, Wu HH, Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000;242:15-29.
6. Alarcon-Vargas D, Ronai Z. p53-Mdm2-the affair that never ends. Carcinogenesis 2002;23:541-7.
7. Jones SN, Ansari-Lari MA, Hancock AR, et al. Genomic organization of the mouse double minute 2 gene. Gene 1996;175:209-13.
8. Liang H, Atkins H, Abdel-Fattah R, Jones SN, Lunec J. Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs. Gene 2004;338:217-23.
9. Brown CY, Mize GJ, Pineda M, George DL, Morris DR. Role of two upstream open reading frames in the translational control of oncogene mdm2. Oncogene 1999;18:5631-7.
10. Bartel F, Taubert H, Harris LC. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2002;2:9-15.
11. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 2001;20:4041-9.
12. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 1996;2:912-20.
13. Balint EE, Vousden KH. Activation and activities of the p53 tumour suppressor protein. Br J Cancer 2001;85:1813-23.
14. Joseph TW, Zaika A, Moll UM. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage. FASEB J 2003;17:1622-30.
15. Dai MS, Zeng S, XJin Y, Sun XX, David L, Lu H. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol 2004;24:7654-68.
16. Korgaonkar C, Zhao L, Modestou M, Quelle DE. ARF function does not require p53 stabilization or Mdm2 relocalization. Mol Cell Biol 2002;22:196-206.
17. Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon GM, Vousden KH. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003;3:577-87.
18. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000;10:94-9.
19. Ganguli G, Wasylyk B. p53-independent functions of MDM2. Mol Cancer Res 2003;1:1027-35.
20. Ma Y, Yuan R, Meng Q, Goldberg I, Rosen EM, Fan S. p53-independent down-regulation of Mdm2 in human cancer cells treated with Adriamycin. Mol Cell Biol Res Commun 2000;3:122-8.
21. Fridman JS, Hernando E, Hemann MT, de Stanchina E, Cordon-Cardo C, Lowe SW. Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res 2003;63:5703-6.
22. Steinman HA, Burstein E, Lengner C, et al. An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J Biol Chem 2004;279:4877-86.
23. Bartel F, Pinkert D, Fiedler W, et al. Expression of alternatively and aberrantly spliced transcripts of the MDM2 mRNA is not tumor-specific. Int J Oncol 2004;24:143-51.
24. Lukas J, Gao DQ, Keshmeshian M, et al. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 2001;61:3212-9.